- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Multi-Channel Engagement Model to Improve ROI
Outsourced healthcare services provider, Ashfield, part of UDG Healthcare, has announced the launch of The Ashfield Solution, an agile, multi-channel engagement model underpinned by a field analytics engine.
The Ashfield Solution addresses the challenges of pharmaceutical companies needing to maintain or improve return on investment (ROI). Utilizing the AshfieldGuide, a sales analytics and planning platform, it provides a more efficient, impactful and agile sales model with the capability to flex resources in ‘real-time’ in reaction to market events.
The new model reportedly helps pharmaceutical companies optimize their investment in light of margin pressure, loss of exclusivity, new product data and new market entrants including biosimilars. It provides analytics capabilities in response to curve modeling, segmentation techniques, mix modeling and geospatial optimisation. In addition, the commercial model is said to deliver engagement optimization and monthly reporting on ROI, call attainment and performance.
For more information visit www.ashfieldhealthcare.com
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
